Retatrutide is an investigational triple hormone receptor agonist, and across its clinical-trial program it has been given as a once-weekly subcutaneous injection rather than an oral tablet. Because no regulator has approved it as of mid-2026, there is no labeled prescribing schedule; every dosing figure in circulation comes from research protocols that escalated the weekly dose gradually toward a target. The records describe investigational regimens tested under supervision, not a regimen any reader could follow as instructions.
In clinical trials retatrutide has been administered as a once-weekly subcutaneous injection using a gradual dose-escalation schedule, but as of mid-2026 it carries no FDA-approved, labeled dosing regimen.
In every published retatrutide trial, the drug has been delivered by subcutaneous injection, deposited into the fatty tissue just beneath the skin rather than into a muscle or vein. The route is dictated by the molecule itself: retatrutide is a peptide, and peptides are broken down by digestive enzymes and absorbed poorly if swallowed, so there is no oral tablet or capsule form.
Across all published clinical trials, retatrutide has been administered exclusively by subcutaneous injection, with no oral formulation, because the peptide is degraded by digestive enzymes if swallowed.
The retatrutide trial program dosed the drug once weekly, with each participant taking a single subcutaneous injection on the same day each week. The molecule's long half-life keeps blood levels relatively steady between doses, so one injection sustains its effect across seven days rather than requiring a daily routine.
Retatrutide was dosed once weekly throughout its trial program, with the seven-day interval held constant while the dose amount, not the injection frequency, changed during escalation.
Titration in the retatrutide trials means participants did not begin at the full target dose; they started low and stepped up on a schedule until reaching an assigned maintenance dose, which they then held for the rest of the study. The exact step sizes and intervals varied between studies, since the program tested multiple maintenance targets and refined its approach as data accumulated, so there is no single universal schedule to cite.
Retatrutide titration started participants at a low weekly dose and stepped up over several weeks to a few months toward an assigned maintenance dose, with the exact step sizes and intervals differing across trials.
Subcutaneous retatrutide injections in the trials were placed where a reliable layer of fatty tissue sits under the skin: most commonly the abdomen away from the navel, the front or outer thigh, and the back of the upper arm. These are the same regions used for insulin and other weekly subcutaneous agonists, which is why the handling is well established even though retatrutide remains investigational.
Retatrutide injections in the trials were placed into the abdomen, thigh, or upper arm with sites rotated to limit local thickening and irritation, and avoided over bruised, scarred, or hardened skin.
The most common and limiting side effects of this drug class are gastrointestinal, and they track how fast the dose rises far more than the dose itself once the body has adjusted. Starting low and stepping up gives the digestive system time to accommodate the slowed gastric emptying and appetite signals, which blunts the nausea, vomiting, diarrhea, constipation, and reduced appetite that appear when an agonist of this type is started or increased too quickly.
The retatrutide dose is escalated gradually because the gastrointestinal side effects of this drug class are tied to how fast the dose rises, and pushing it up too quickly raises the risk of side effects severe enough to stop treatment.
As of mid-2026, retatrutide has not been approved by the FDA or other major regulators, so there is no official, labeled dosing schedule of the kind that accompanies a marketed medicine. The dosing figures that circulate come from published clinical-trial protocols and results, which describe what researchers tested under controlled conditions, not what a clinician would be authorized to prescribe.
As of mid-2026 retatrutide has no FDA-approved, labeled dosing schedule, and every circulating dosing figure comes from investigational trial protocols rather than an authorized prescribing label.
Retatrutide trials did not test a single strength; they evaluated a range of weekly maintenance doses against each other and against placebo within the same study to map the relationship between dose and response. The studies showed a dose-dependent pattern, with higher maintenance doses producing the larger reductions in body weight, though higher doses also tended to bring more gastrointestinal side effects, so the data are read with both efficacy and tolerability of each level in view.
| Dimension | Lower maintenance doses | Higher maintenance doses |
|---|---|---|
| Weight reduction | Smaller reported reductions | Larger reported reductions |
| Gastrointestinal side effects | Generally fewer | Tended to be more frequent |
| How the data are read | Weighed for tolerability | Weighed against the side-effect trade-off |
Retatrutide trials evaluated multiple weekly maintenance dose levels against placebo and showed a dose-dependent pattern, with higher doses producing larger weight reductions but also more gastrointestinal side effects, and the specific milligram figures remain investigational.
Educational use only. This article describes what the published scientific and clinical literature reports about Retatrutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
